Acucela Inc. , a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy ... (more)
http://ift.tt/1eYqqWX
http://ift.tt/1eYqqWX
No comments:
Post a Comment